Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 19.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,464,237 shares of the company's stock after buying an additional 241,052 shares during the period. Vanguard Group Inc. owned about 3.91% of Entrada Therapeutics worth $25,317,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of TRDA. KLP Kapitalforvaltning AS purchased a new stake in shares of Entrada Therapeutics in the fourth quarter valued at about $36,000. AlphaQuest LLC acquired a new position in shares of Entrada Therapeutics in the fourth quarter worth $70,000. China Universal Asset Management Co. Ltd. acquired a new stake in Entrada Therapeutics in the 4th quarter valued at about $137,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Entrada Therapeutics by 34.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company's stock worth $226,000 after acquiring an additional 3,644 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Entrada Therapeutics by 44.0% during the 4th quarter. SG Americas Securities LLC now owns 14,036 shares of the company's stock worth $243,000 after buying an additional 4,291 shares during the last quarter. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Entrada Therapeutics in a report on Monday, March 31st.

Entrada Therapeutics Stock Up 3.4 %

NASDAQ:TRDA traded up $0.27 during mid-day trading on Friday, reaching $8.13. 158,883 shares of the stock were exchanged, compared to its average volume of 123,930. The stock has a market capitalization of $305.65 million, a P/E ratio of 5.11 and a beta of 0.04. Entrada Therapeutics, Inc. has a 1 year low of $7.10 and a 1 year high of $21.79. The company has a 50 day simple moving average of $10.38 and a 200-day simple moving average of $14.66.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.69. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The firm had revenue of $12.25 million for the quarter, compared to analysts' expectations of $11.95 million. As a group, research analysts predict that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.